News
Article
Author(s):
In case you missed it, this week we had news about Clinuvel's phase III trial enrollment for vitiligo, Sun Pharma's BLU-U device for actinic keratosis, a botanical-based nutraceutical for acne patients and more.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Advancing Atopic Dermatitis Treatment by Understanding the Role of Multitargeted Therapies
Explore the evolving landscape of dermatology as experts emphasize the importance of cross-specialty collaboration and patient-centered care in aesthetic medicine.
AI Model Creates Successful Treatment Regimens for Women with Hair Loss
In a new study, AI-driven personalized treatments significantly enhanced hair growth and scalp health, offering innovative solutions for hair loss management.
ASAP Protocol Yields 82% Keloid Resolution
Discover an innovative non-surgical keloid treatment protocol that achieves high satisfaction and low recurrence rates for patients with darker skin tones.
Closing the Gap in Pediatric Atopic Dermatitis: Experts Push for Steroid-Free Advancements
Discover the latest advancements in pediatric atopic dermatitis care, featuring expert insights on innovative treatments and family-centered management strategies.
LEVEL UP Trial Sets New Benchmark for Atopic Dermatitis Treatment
Christopher Bunick, MD, PhD, explains why composite endpoints are now critical for evaluating patient outcomes in AD therapy.
Melanoma Research Foundation and Glowbar Join Forces to Fight Skin Cancer
In honor of Melanoma Awareness Month, Glowbar CEO Rachel Liverman spoke to Dermatology Times about this new collaboration, which aims to increase patients' daily sunscreen use by 2026.
Uncovering Inequities in Hidradenitis Suppurativa Trials
Explore the critical need for diversity in hidradenitis suppurativa clinical trials to address health inequities and improve patient outcomes.
Expanding Global Access to Dermatology: GLODERM and CeraVe Awards Fuel Community-Driven Change
Seven dermatologists have received GLODERM x CeraVe Access Grants to expand skin care access in underserved communities worldwide.
Experts Look Ahead to the Advancements in AD Research
To hear more about AD advancements from Shahriari and Lio in person, register to attend the Revolutionizing Atopic Dermatitis Conference 2025 in Nashville, Tennessee, on June 6 and 7.
What to Know When Targeting IL-13 vs IL-31 in Atopic Dermatitis
Raj Chovatiya, MD, PhD, MSCI, discusses how IL-13 and IL-31 inhibitors represent distinct yet complementary mechanisms in the management of atopic dermatitis.
New Meta-Analysis Supports Targeted Vitiligo Therapies
Explore the promising role of JAK inhibitors in vitiligo management, highlighting efficacy, safety, and potential combination therapies for enhanced results.
New Survey Confirms Acne Patients Have More Trust in Clinicians than Social Media Influencers
Even with the recent rise of social media guidance, patients still trust dermatologists over social media influencers for acne treatment.
Botanical-Based Nutraceutical Improves Acne
Discover how a novel nutraceutical significantly improves mild to moderate acne in a 12-week clinical trial, offering a holistic approach to skin health.
Dual Inhibitor TRIV-509 Shows Promise for Rapid Improvement in Atopic Dermatitis
Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.
Tyk2 Inhibition Prevents Islet Inflammation and Delays Type 1 Diabetes Development in Mice
New research reveals a promising strategy to slow type 1 diabetes progression by targeting inflammation with an existing psoriasis drug.
This review of the latest dermatologic studies includes insights into switching PD-1 to BRAF + MEK inhibition, clinical outcomes, and prognosis in atypical fibroxanthoma, and more.
Toughness Is More Than Skin-Deep: Who Cries and Who Doesn’t in a Dermatology Clinic
Hershel Dobkin, MD, FAAD, discusses the surprising truth about toughness in dermatology, unexpected patient reactions, and the emotional depth behind appearances.
Prolonged Use of Oral Corticosteroids in Atopic Dermatitis Linked to Increased Cardiovascular Risks
Extended oral corticosteroid therapy in patients with atopic dermatitis significantly increases cardiovascular and thrombotic risks, urging careful treatment evaluations.
Clinuvel Completes Enrollment in Phase III Afamelanotide Vitiligo Trial
Clinuvel's phase III trial CUV105 enrolls 200 patients, exploring afamelanotide as a promising systemic treatment for vitiligo.
UVB Phototherapy and Tofacitinib Are Effective for Combined Vitiligo Treatment
Combining tofacitinib with UVB therapy significantly enhances vitiligo treatment outcomes, improving recovery rates and quality of life for patients.
Quoin Announces Positive QRX003 Data for Pediatric Peeling Skin Syndrome
A pediatric patient with Peeling Skin Syndrome observed overall skin healing with no adverse events after 12 weeks of treatment.
AbbVie and ADARx Join Forces to Advance Next-Generation siRNA Therapies
The new partnership brings RNA-targeted innovation to dermatology-relevant disease areas like autoimmunity and cancer.
Recludix Unveils First BTK SH2 Domain Inhibitor
Recludix Pharma unveils a groundbreaking BTK SH2 inhibitor, showcasing superior selectivity and efficacy for chronic spontaneous urticaria treatment at SID 2025.
Practice and Personal Planning: Tactics That Reduce Taxes and Protect Assets
Explore effective tax and asset protection strategies for dermatologists, including retirement plans and life insurance options for wealth management.
Risankizumab Effective in Difficult-to-Treat Psoriasis Areas
Discover the promising results of risankizumab for treating genital and scalp psoriasis, showcasing significant improvements in symptoms and quality of life.
Artax Biopharma's AX-158: A Novel Approach to T Cell-Driven Inflammation in Psoriasis
Scott Batty, MD, and Chris VanDeusen, PhD, provided insights on AX-158's phase 2a results, presented at the SID Annual Meeting.
Lurie Children’s Becomes First Treatment Center for Zevaskyn Gene Therapy in Patients with RDEB
ZEVASKYN, the first FDA-approved gene therapy for wounds in recessive dystrophic epidermolysis bullosa, is now available at Lurie Children's Hospital.
IL-23 and IL-17 Inhibitors Reduce Cardiovascular Outcomes in Statin-Treated Psoriasis Patients
Biologics significantly lower cardiovascular risks in psoriasis patients on statins, highlighting their dual benefits for skin and heart health.
New Guidance Aims to Improve Genital Psoriasis Treatment
New guidelines from the Genital Psoriasis Wellness Consortium highlight the significant impact of genital psoriasis on patients, emphasizing improved diagnosis and personalized treatment.
New Antiaging Senotherapeutics: Senolytics and Senomorphics
Explore the latest advancements in senotherapeutics, targeting aging through senolytics and senomorphics for enhanced skin health and healing.
FDA Approves Sun Pharma's New LED BLU-U Device for AK
Sun Pharma's innovative BLU-U device gains FDA approval, revolutionizing actinic keratosis treatment with advanced blue light therapy.
GLP-1 Therapy Offers Dual Benefits for Skin and Heart
GLP-1 receptor agonists show promise in reducing cardiovascular risks for patients with chronic inflammatory skin diseases like psoriasis and atopic dermatitis.
Q&A: Laura Scott, MD, FAAD, and Sun Bum on the Road to Accessible Sun Safety
Sun safety awareness grows with Laura Scott, MD, FAAD, and Sun Bum's "Trust the Bum Tour," offering free SPF products and education to diverse communities nationwide.
Evidence Highlights Thiamidol’s Efficacy and Safety in Hyperpigmentation Treatment
Thiamidolemerges as a promising treatment for hyperpigmentation, showcasing superior efficacy and safety compared to traditional options like hydroquinone.
Transforming Risk Stratification in Melanoma and Squamous Cell Carcinoma
Integrating molecular testing into melanoma and SCC management enhances risk assessment and personalizes treatment, revolutionizing patient care in dermatology.
Psoriasis and Cellulitis Burden Has Increased in the US, According to New Posters
Recent posters at SID revealed significant increases in psoriasis and cellulitis cases in the US, highlighting urgent needs for prevention and treatment strategies.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.